Anti-endothelial cell antibodies in patients with COPD

L. Taraseviciene-Stewart, V. Kraskauskiene, N. Burns, N. Voelkel (Denver, CO, United States Of America)

Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session: Cellular and molecular aspects of pulmonary hypertension
Session type: Electronic Poster Discussion
Number: 496
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Taraseviciene-Stewart, V. Kraskauskiene, N. Burns, N. Voelkel (Denver, CO, United States Of America). Anti-endothelial cell antibodies in patients with COPD. Eur Respir J 2007; 30: Suppl. 51, 496

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-endothelial cell antibodies in patients with idiopathic nonspecific interstitial pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 308s
Year: 2006

Detection of serum anti-endothelial cell antibodies (AECA) in COPD rats
Source: Annual Congress 2011 - Cell biology of lung disease
Year: 2011

Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD)
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 339s
Year: 2006

Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018

Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019

Influenza antibodies in patients with COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 338s
Year: 2003

Antirecoverin autoantibodies in sera of patients with non-small cell lung cancer in the absence of cancer-associated retinopathy
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002

High prevalence of serum IgA antibodies against gliadin in patients with interstitial lung diseases confirmed by immunoblotting
Source: Eur Respir J 2003; 22: Suppl. 45, 227s
Year: 2003

Change of T2-markers in patients with severe uncontrolled asthma treated by monoclonal antibodies: 1 yr follow up
Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Year: 2021


Anti-elastin immunity in COPD patients
Source: Annual Congress 2011 - COPD: mechanisms and biomarker
Year: 2011

Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 923-925
Year: 2010


Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020
Year: 2020



Antinucleosome autoantibody in a patient with sarcoidosis and antiphospholipid antibodies
Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases
Year: 2010

Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020


Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001

Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

The outcomes of lung transplantation in patients with bronchiectasis and antibody deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 178s
Year: 2004